These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36747946)

  • 1. Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis.
    Liu L; Li H; Zhang Y; Zhang J; Cao Z
    Heliyon; 2023 Jan; 9(1):e13113. PubMed ID: 36747946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
    Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
    J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
    Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
    J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.
    Tan YW; Wang JM; Zhou XB
    World J Hepatol; 2023 Feb; 15(2):237-254. PubMed ID: 36926239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.
    Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M;
    J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
    Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response.
    Zhang RN; Pan Q; Zhang Z; Cao HX; Shen F; Fan JG
    Hepat Mon; 2015 May; 15(5):e27909. PubMed ID: 26045709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
    Chien RN; Liaw YF
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Meta-Analysis of How Nonalcoholic Fatty Liver Disease Affect Antiviral Treatment of Patients with e Antigen-Positive Chronic Hepatitis B.
    Chen Y; Liu Q; Han J; Gao S; Xiao Q; Huang X; Lu L; Zhou X
    Emerg Med Int; 2022; 2022():4774195. PubMed ID: 36225715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia.
    Yang M; Wei L
    Liver Int; 2022 Aug; 42(9):1981-1990. PubMed ID: 35373500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    European Association for the Study of the Liver
    J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
    Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
    BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.
    Pan Q; Zhang RN; Wang YQ; Zheng RD; Mi YQ; Liu WB; Shen F; Chen GY; Lu JF; Zhu CY; Zhang SY; Chen YM; Sun WL; Fan JG
    World J Gastroenterol; 2015 Jul; 21(28):8605-14. PubMed ID: 26229402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B.
    Cho H; Chang Y; Lee JH; Cho YY; Nam JY; Lee YB; Lee DH; Cho EJ; Yu SJ; Kim YJ; Lee JM; Yoon JH
    J Clin Gastroenterol; 2020 Aug; 54(7):633-641. PubMed ID: 31033805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis.
    Kumar A; Sharma A; Duseja A; Das A; Dhiman RK; Chawla YK; Kohli KK; Bhansali A
    J Clin Exp Hepatol; 2013 Mar; 3(1):12-8. PubMed ID: 25755466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of reactive oxygen species and adiponectin for chronic HBV infection combined with nonalcoholic fatty liver diseases].
    Xu L; Zhong Y; Su ST; Liu YG; Lyu FN; Zhou XL; Ren JQ; Li P; Shi RF; Jiang Y; Fan JG; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):247-253. PubMed ID: 32306658
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.
    Cho EJ; Kwack MS; Jang ES; You SJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():17-22. PubMed ID: 22156481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.